David R. Bauer
Lawyers
Filters
Editas Medicine, Inc. $108.6 Million Initial Public Offering
Davis Polk advised the active joint book-running managers and representatives of the underwriters in connection with the $108.6 million initial public offering of 6,785,000 shares of common…
Mylan N.V. $1 Billion Notes Offering
Davis Polk advised the representatives of the initial purchasers on two Rule 144A/Regulation S offerings by Mylan N.V. of $500 million aggregate principal amount of its 3.000% senior notes…
Davis Polk Advises Fandango on Its Acquisition of Ingresso.com
Davis Polk is advising Fandango in connection with its acquisition of Ingresso.com from B2W Companhia Digital, a Latin American e-commerce company. The financial terms of the transaction…
Biogen Inc. $6 Billion Senior Notes Offering
Davis Polk advised the underwriters, in connection with the SEC-registered offering by Biogen Inc. of $1.5 billion principal amount of 2.900% senior notes due 2020, $1.0 billion principal…
Aimmune Therapeutics, Inc. $183.9 Million Initial Public Offering
Davis Polk advised the underwriters in connection with the $183.9 million initial public offering of Aimmune Technologies, Inc. Aimmune Therapeutics sold 11,499,999 shares of its…
Davis Polk Advises Hotel Urbano on its Strategic Partnership with Priceline
Davis Polk advised Hotel Urbano in connection with its strategic partnership with The Priceline Group. The partnership consists of a $60 million minority investment by Priceline and a…
Avid Technology, Inc. $125 Million Convertible Senior Notes Offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Avid Technology, Inc.(“Avid”) of an aggregate principal amount of $125 million of its 2.00% convertible…